



Imvexxy[®]
(estradiol vaginal inserts)
4 mcg • 10 mcg

Bijuva[®] 1mg/100mg
(estradiol and progesterone) capsules

Annovera[®]
(segesterone acetate and
ethinyl estradiol vaginal system)
Delivers 0.15 mg/0.013 mg per day

TherapeuticsMD[®]

For Her. For Life.

Cowen Conference
March 3, 2020

*Building the Premier
Women's Health
Company*



Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission (SEC), including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: our ability to maintain or increase sales of our products; our ability to develop and commercialize IMVEXXY, ANNOVERA, BIJUVA and our hormone therapy drug candidates and obtain additional financing necessary therefor; whether we will be able to comply with the covenants and conditions under our term loan facility, including the conditions to draw an additional tranche thereunder and whether our lender will make that tranche available; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of our current or future approved products or preclude the approval of our future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; our ability to protect our intellectual property, including with respect to the Paragraph IV notice letter the company received regarding IMVEXXY; the length, cost and uncertain results of future clinical trials; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the ability of our licensees to commercialize and distribute our products; the ability of the company’s marketing contractors to market ANNOVERA; the effects of laws, regulations and enforcement; the competitive nature of the industries in which we conduct our business; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock, including the effect of any sales of common stock by our executive officers or directors, whether in connection with the expiration of stock options or otherwise; and the concentration of power in our stock ownership. This non-promotional presentation is intended for investor audiences only.

Portfolio Approach to Women's Health

Empowering Women For Life

Annovera[®]
(segesterone acetate and
ethinyl estradiol vaginal system)
Delivers 0.15 mg/0.013 mg per day

vitaMedMD[®]
Prenatal Vitamins

Annovera[®]
(segesterone acetate and
ethinyl estradiol vaginal system)
Delivers 0.15 mg/0.013 mg per day

Bijuva[®] 1mg/100mg
(estradiol and progesterone) capsules

Imvexxy[®]
(estradiol vaginal inserts)
4 mcg - 10 mcg



- Innovative customer centric products, chronic conditions, large markets
- Products transition from one to the next through the various stages of life
 - contraception → pregnancy → contraception → vasomotor symptoms → vulvar and vaginal atrophy
- 200 sales representatives focused on OB/GYN women's health call point
- Broad and growing payor coverage and reimbursement established
- Launch plans to take advantage of synergistic portfolio of products

Foundational Elements to Accelerate Revenue Growth 2020

Portfolio Awareness & Education



Broad Payor Access



New Distribution Channels



All trademarks are the property of their respective owners.

Significant Payor Coverage and Growing

	Coverage February 20, 2020	Target Coverage Year-end 2020
ANNOVERA		
Commercial	75%*	80%*
IMVEXXY		
Commercial	72%	75%
Part D	29%	70%
BIJUVA		
Commercial	56%	75%

Awaiting IMVEXXY Part D decisions from Humana, Wellcare and ESI; potential total unrestricted coverage of up to 40% by April 1st

Source: MMIT February 20, 2020

*Annovera coverage includes unrestricted access and coverage with a step edit/prior authorization. Currently 65% unrestricted, 11% step/prior authorization.

A large teal circular graphic with a white center, containing the text 'PRODUCT OVERVIEW & COMMERCIAL UPDATES'. The background features a light gray hexagonal grid pattern.

PRODUCT OVERVIEW & COMMERCIAL UPDATES


3 Products in Launch Mode

Shifted from a clinically innovative company to a commercially successful company



Sales Force Redeployed to Provide More Effective Portfolio Coverage

150 Women's Healthcare Specialists



1

Annovera
(segesterone acetate and ethinyl estradiol vaginal system)
Delivers 0.15 mg/0.013 mg per day

2


Imvexxy
(estradiol vaginal inserts)
4 mcg - 10 mcg

3

Bijuva 1mg/100mg
(estradiol and progesterone) capsules



30-40 Menopause Specialists



1

Bijuva 1mg/100mg
(estradiol and progesterone) capsules

2

Imvexxy
(estradiol vaginal inserts)
4 mcg - 10 mcg

2020 Brand Strategy

Brand prioritization establishes focused and disciplined capital allocation to drive net revenue growth in 2020 with a view toward profitability in 2021

1

Annovera[®]
(segesteron acetate and ethinyl estradiol vaginal system)
Delivers 0.15 mg/0.013 mg per day

- Favorable payer dynamics and coverage
- Highest net revenue per unit across portfolio
- Largest women's health category
- Fastest payback period on marketing investments
- Full scale launch March 1st

2

Imvexxy[®]
(estradiol vaginal inserts)
4 mcg • 10 mcg

- Goal to surpass Premarin Vaginal Cream on a monthly basis
- Broad commercial payer coverage established
- Opportunity to leverage existing large base of prescribers and patients to grow market share
- Increase HCP and DTC marketing to drive demand

3

Bijuva[®] 1mg/100mg
(estradiol and progesterone) capsules


- Commercial payer coverage still growing
- Increased HCP awareness and adoption needed
- Focus on expanding BIO-IGNITE partners and pull through
- Establish product differentiation through peer to peer engagement
- Potential approval of lower dose Q4 2020

- **Increase sales and marketing investment to drive net revenue growth in 2020**

DTC - direct to consumer

ANNOVERA Summary

- **Only FDA-approved long-lasting reversible contraception that is patient-controlled and procedure-free**
 - Empowers women to be in control of their fertility and menstruation
 - ANNOVERA is the only user-directed single 1-year (13-cycles) birth control product (used in repeated cycles for 3-weeks in/1-week out)
- **One of the lowest doses of ethinyl estradiol - 13 mcg**
- **Only product with new progestin - segesterone acetate¹**
 - No androgenic, estrogenic, or glucocorticoid effects at contraceptive doses*
- **As effective as a pill without the daily hassle**
- **High patient satisfaction in a phase 3 clinical trial acceptability study of 905 women²**
 - ~90% overall satisfaction, adherence (94.3%) and continuation (78%)
- **Soft, pliable ring**
- **Does not require refrigeration**
- **Demonstrated acceptable side effect profile including low rates of discontinuation related to irregular bleeding (1.7%)****




*Based on pharmacological studies in animals and in vitro studies. The clinical significance of these data is not known.

**In clinical trials, 12% of participants discontinued due to an adverse reaction.

1. Narender Kumar, Samuel S. Koide, Yun-Yen Tsong, and Kalyan Sundaram. 2000. "Nestorone: a Progestin with a Unique Pharmacological Profile," *Steroids* 65: 629-63
2. Merkatz, Ruth B., Marlina Plagianos, Elena Hoskin, Michael Cooney, Paul C. Hewett, and Barbara S. Mensch. 2014. "Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: Development of a model; implications for introduction," *Contraception* 90(5): 514-521.

ANNOVERA – Patient-Controlled and Procedure-Free Long-Lasting Contraception*



*ANNOVERA is inserted for 21 continuous days and removed for 7 days for 13 cycles (one year).

ANNOVERA Growth Levers

Lead Product for Spend and Focus



Sales Force Focus

- Full scale launch March 1st
- Lead product designation for Women's Healthcare Salesforce



Consumer Advertising and Public Relations Effort

- Focus on **Empowerment** and **Control**^{1,2}
- Disruptive Consumer Campaign Planned Launch in March
- Public Relations Initiatives



Expand into New Channels and Populations

- Online Platforms including Pillpack, PlushCare, and Pill Club
- WSI to market to the Department of Defense and Veteran's Administration
- Puerto Rico Distribution
- Afaxys to meet the needs of public health clinics, college and university health clinics, and city, county, state and federal facilities

¹ANNOVERA is inserted for 21 continuous days and removed for 7 days for 13 cycles (one year)

IMVEXXY's Unique Product Attributes

 **Imvexxy**[®]
(estradiol vaginal inserts)



- Indicated for moderate to severe dyspareunia
- Small, digitally inserted, softgel vaginal insert that dissolves completely
- **Easy to use without the need for an applicator**
- **Mess-free** administration
- Use **any-time of day**
- **Lowest approved doses** of estradiol 4 mcg and 10 mcg
- **Efficacy demonstrated as early as 2 weeks** (secondary endpoint) and maintained through week 12 in clinical studies
- PK data - **No increase in systemic hormone levels** beyond the normal postmenopausal range*
- Mechanism of action and dosing that are familiar and comfortable
- No patient education required for dose preparation or applicators
- **Dose packaging to optimize compliance and convenience**

➔ **High patient satisfaction resulting in high refill rates**

IMVEXXY: 4.4 fills/yr¹ (through December 2019)

- Vaginal creams: average 1.5 fills/yr²
- Vaginal tablets: average 3.5 fills/yr²

*The clinical relevance of systemic absorption rates for vaginal estrogen therapies is not known.

1) Average number of fills for all patients is calculated as Total Rx / Total Patients.

2) Total Rx/Patient Count

IMVEXXY Investment Across Multiple Levers

Sales Force

- Promoted by all Sales Representatives
- 4,200 current heavy writers representing 20% of high volume VVA writers
- Goal to increase depth of writing among 20,000 prescribers who have prescribed IMVEXXY

Marketing

- Increased overall funding
- Heavier investment in consumer marketing throughout the year

2020 Goal: surpass Premarin® Vaginal Cream on a monthly prescription basis by year end

- Current average monthly TRX of Premarin Vaginal Cream: 80K TRx*

*IQVIA data

All trademarks are the property of their respective owners.

Increase Awareness of IMVEXXY That Creates the Standard of Care for VVA Patients

IMVEXXY's Strategic Imperatives Will ELEVATE, EDUCATE, and ACTIVATE "Her"

KEY
OPPORTUNITIES

Show her she doesn't need to
put up with symptoms,
she can treat them

Introduce IMVEXXY
as the standard of care
to treat her symptoms

Support conversations
with her HCP around treating
symptoms with IMVEXXY

STRATEGIC IMPERATIVES

ELEVATE

- Help her realize her symptoms are related to menopause, and they are treatable
- Show her the way forward so she feels excited to explore treatment options

EDUCATE

- Position Rx treatments, specifically IMVEXXY and its value proposition, as the most effective treatment for her symptoms
- Help her feel more comfortable talking about her symptoms and give her the tools to have a productive conversation with her HCP

ACTIVATE

- Empower her to confidently self-advocate, get the conversation with her HCP started and ask for IMVEXXY

JOURNEY



BIJUVA's Unique Product Attributes

BIJUVA OFFERS^{1,2,4-7}



THE CONVENIENCE OF ONE

The convenience of a single-capsule combination of 2 hormones, which may improve compliance



A PLANT-BASED TREATMENT

Estradiol and progesterone are plant-based, not animal-sourced, and contain no peanut allergens

BIJUVA WAS STUDIED IN A 1-YEAR CLINICAL TRIAL^{1,2,8,9}



DEMONSTRATED EFFICACY

A sustained steady state of estradiol reduced the frequency and severity of hot flashes*



WEIGHT AND BLOOD PRESSURE

No demonstrated impact on weight or blood pressure



ENDOMETRIAL PROTECTION

Demonstrated endometrial safety† and >90% amenorrhea rates‡*



MAMMOGRAMS

No clinically meaningful changes in mammograms

* Efficacy was evaluated in a 12-week substudy. The pharmacokinetics of BIJUVA show a steady state of estradiol that is sustained over 24 hours. The steady state is achieved at 7 days.²

† Endometrial hyperplasia has been reported to occur at a rate of ≤1% in women receiving BIJUVA, which is consistent with the expected incidence rate in a menopausal population.¹

‡ The cumulative amenorrhea rate in patients receiving BIJUVA was 56.1% with rates increasing over time. Cumulative amenorrhea was defined as the absence of bleeding or spotting for a cumulative period from cycle 1 to 13.^{2,3}

References: 1. Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. *Climacteric*. 2018;21(4):346-354. 2. Prometrium [package insert]. Marietta, GA: Solvay Pharmaceuticals, Inc; 2009. 4. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. *Menopause*. 2017;24(7):728-753. 5. Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Woode DE; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. *Endocr Pract*. 2011;17 Suppl 6:1-25. 6. Simon JA. What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead? *Menopause*. 2014;21(7):1-15. 7. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. *Obstet Gynecol*. 2013;121(4):887-890. 8. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. *Arterioscler Thromb Vasc Biol*. 2010;30(2):340-345. 9. Bińkowska M. Menopausal hormone therapy and venous thromboembolism. *Prz Menopausalny*. 2014;13(5):267-272.

Elevate the BIJUVA Scientific Narrative & Reset Foundational Knowledge to Drive Meaningful Differentiation

Close Partnership with Medical Affairs to Identify Data from REPLENISH & Key Studies

Efficacy & Safety
Sub-analyses (by age,
smoking status)



Cardio-
metabolic Data



QoL/Sleep



Evidence
Based
Science

Bone Turnover/
Bone Markers



Assessing Risk
of Breast Cancer



Introduce
Low-dose BIJUVA
(if approved)


**BIJUVA 0.5mg/100mg
Preliminary Launch Plan**

- Virtual Launch Meeting
- Updated Sell Sheet & Materials
- Speaker Deck Updates

BIJUVA Targeted Approach in 2020

Preparing for Full Launch in 2021

Menopause Specialist Deployment



Targeted approach supporting BIO-IGNITE



A dedicated team of sales reps and the TXMD BIO-IGNITE staff will focus their efforts to grow BIJUVA through BIO-IGNITE partners

163 pharmacies live

Potential Second Dose


Bijuva[®] 0.5mg/100mg
(estradiol and progesterone) capsules

PDUFA November 2020




FINANCIAL UPDATE

Trend in Total Net Revenue and Calculated Net Revenue Per Unit




Net Revenue by Product

- Prenatal Vitamins
- BIJUVA
- IMVEXXY
- ANNOVERA



Q3 2019

Q4 2019




* Calculated Net Revenue per Unit = GAAP Net Revenue divided by number of prescriptions filled by patients in period

Trend in Total Net Revenue and Calculated Net Revenue Per Unit


Net Revenue by Product

- Prenatal Vitamins
- BIJUVA
- IMVEXXY
- ANNOVERA



Q3 2019

Q4 2019




Q2 2019

Q3 2019

Q4 2019


* Calculated Net Revenue per Unit = GAAP Net Revenue divided by number of prescriptions filled by patients in period

ANNOVERA Net Revenue Actual



Cash Balance at End of Each Quarter with Equity Raise/Debt Funding Post Quarter End

(Millions)



2020 Cost Containment Measures

Goal to reinvest the savings into marketing initiatives



Drive Net Revenues:

- Invest appropriate financial resources to drive net revenue growth for our brands



Control Operating Expenses:

- Scrutinized internal cost structure and reduced spend on the following:
 - Non-revenue generating projects
 - Headcount optimization / reduction
 - Eliminated multiple clinical development roles
 - Paused pipeline development projects

2020 Financial Guidance

Annual Net Revenue Guidance

- Company projects 2020 net product revenue to be between \$90M to \$110M

Key Assumptions:

- Net product revenue during the second half of the year will be significantly larger than the first half with the majority coming from ANNOVERA and IMVEXXY
- High deductible and annual copay resets expected to impact 1Q20 net revenue for the menopause products
 - Expect 1Q20 net revenue to come in below 4Q19 net revenue
 - 1Q20 industry wide headwind built into our annual 2020 financial guidance

* Note: In 2020, the company will utilize Symphony Health IDV national data for reporting prescriptions dispensed to patient's by pharmacies as we believe Symphony Health data most accurately reflects the data.

2020 Goals & Milestones

- Full launch of ANNOVERA for TXMD's sales force will begin on March 1st
- Leverage new distribution channels to enter new markets that create additional revenue opportunity outside TXMD's direct sales and marketing efforts
- For IMVEXXY, goal is to pass the VVA branded leader, Premarin vaginal cream, on a monthly prescription basis by the end of 2020
- For BIJUVA, utilize menopause specialist sales force to provide the right focus to build the foundation and allow us to scale BIJUVA in the coming years
- Become EBITDA positive in 2021

The Power of the Portfolio

Multiple Paths to \$1B of Sales

Percent of Market Based on Patient Count of 2.3M and 4 fills per year

Average Net Revenue / Unit	25%	35%	45%	55%
\$80	\$184M	\$257.6M	\$331.2M	\$404.8M
\$100	\$230M	\$322M	\$414M	\$506M

Total Addressable FDA Market : 3.8M

Total Addressable Compounding Market : 12M

Percent of Total Addressable Market

Average Net Revenue / Unit	25%	35%	45%	55%
\$80	\$316M	\$442.4M	\$568.8M	\$695.2M
\$100	\$395M	\$553M	\$711M	\$869M

Total Addressable Birth Control Market NRx: 28M

Average Net Revenue / Unit	1.0%	1.5%	2.0%	2.5%
\$1,000	\$280M	\$420M	\$560M	\$700M
\$1,250	\$350M	\$525M	\$700M	\$875M
\$1,500	\$420M	\$630M	\$840M	\$1.05B
\$1,750	\$490M	\$735M	\$980M	\$1.2B



Diversified risk with 3 FDA-approved products, creating multiple paths to \$1B peak sales opportunity
 Example: \$230M (IMVEXXY), \$395M (BIJUVA) and \$420M (ANNOVERA) = \$1B peak sales potential

The Power of a Women's Health Portfolio

Annovera[®]
 (segesterone acetate and ethinyl estradiol vaginal system)
 Delivers 0.15 mg/0.013 mg per day

 **vitaMedMD**[®]
 Prenatal Vitamins

Annovera[®]
 (segesterone acetate and ethinyl estradiol vaginal system)
 Delivers 0.15 mg/0.013 mg per day

 **Bijuva**[™] 1mg/100mg
 (estradiol and progesterone) capsules

 **Imvexxy**[®]
 (estradiol vaginal inserts)
 4 mcg • 10 mcg



CONTRACEPTION

PRENATAL CARE

CONTRACEPTION/
 FAMILY PLANNING -
 PERIMENOPAUSE

VASOMOTOR
 SYMPTOMS


DYSPAREUNIA
 (Vulvar & Vaginal
 Atrophy)



REPRODUCTIVE HEALTH



MENOPAUSE MANAGEMENT



Appendix

Build out of Commercial Expertise

Commercial Leadership Team



Chris Gish – Sales Lead

- Senior Sales Leader with 29 years of experience in pharmaceutical sales leadership
- Experience in large and small pharmaceutical companies including Pfizer, Sunovion, Alder-Bio
- Have launched 20+ brands over the course of his career
- Unique expertise in optimizing pharmaceutical sales organizations



Tyra Riehl – Training Lead

- Senior leader with expertise in sales training and leadership development
- 22 years in small and large biotech and pharmaceutical companies including Searle, Sunovion, Quest and Alkermes



Mike Steelman – Market Access Lead

- Senior leader access positions at Pfizer and Sanofi with United States and International responsibility
- 22 years of pharma experience with 13 years in access
- Was responsible for 1/3 of Pfizer's National Payor Accounts including government sector



Kristen Landon – Marketing Lead

- Women's Health commercial leader with prior tenures at Allergan, Radius Health, and Sprout
- 24 years' experience in pharmaceutical marketing, sales, sales leadership, and business development
- Category experience in contraception, menopause, osteoporosis, sexual dysfunction, infertility, and infections
- Brands include Lo Loestrin, Estrace, Tymlos, Generess, Liletta, ella, Addyi, Crinone, and Solosec



Erika Guay – Menopause Brand Lead

- Senior leader with over 15 years of marketing experience at Pfizer
- Brand experience across multiple categories including, Women's Health, Depression, Cardiovascular & Dermatology



Jerrold McRae- Reproductive Brand Lead

- Sales and marketing and strategy leader at Pfizer for 14 years
- Brand experience across multiple categories including Women's Health (Estring), Pain (Lyrica), Urology (Detrol LA, Viagra)



Dedra Lyden – Strategic Partnerships

- Launched and continues to lead the expansion of Bio-Ignite
- 16 years of Pharmaceutical experience across BD, Sales, Sales leadership

Understanding Contraceptive Reimbursement

- Under the health reform law (Affordable Care Act), all benefit plans must cover certain Preventative Care Medications like contraceptives without a generic equivalent at 100% - without charging a copay, coinsurance or deductible
- The following slides are examples of how these programs are structured with two of the largest Payers

OptumRx Preventative Care List Adoption

\$0 Cost Share Products

“Under the Health reform law (Affordable Care Act), benefit plans must cover certain Preventative Care Medications at 100% - without charging a copay, coinsurance or deductible”



For members
Effective: January 1, 2020

Preventive Care Medications

\$0 Cost-Share Medications & Products^{1, 2, 3}



Women's Health: Birth Control Products continued...

Generic Ortho Tri-Cyclen sold as:
Norgestimate/Ethinyl Estradiol
Tri-Estaryll
Tri-Femynior
Tri-Linyah
Tri-Mili
Tri-Previfem
Tri-Sprintec
Tri-Vylibra
Trinessa

Generic For Ortho Tri-Cyclen Lo sold as:
Norgest/Ethi Estradio
Tri-Lo-Estaryll
Tri-Lo-Marzia
Tri-Lo-Mili
Tri-Lo-Sprintec
Tri-Vylibra Lo
Trinessa Lo

Generic Ovcon-35 sold as:
Balziva
Briellyn
Philtth
Vyfemla
Zenchent

Generic Ovral sold as:
Ogestrel

Generic Quartette sold as:
Fayosim
Levonor/Ethi tab Estradio
Riveisa

Generic Safaryl sold as:
Dros/Eth Esti tab Levomefo
Tydemy

Generic Seasonale sold as:
Introvale
Jolessa
Levonor/ethinyl estradiol
Quasense
Setiakih

Generic Seasonique sold as:
Amethlia
Ashlyna
Camrese
Daysee
Levonor/ethi estradio
Simpesse

Generic Tri-Norinyl 28 sold as:
Aranelle
Leena

Generic Triphasil sold as:
Empresse-28
Levonest
Levonor/Ethi
Myzitra
Trihora-28

Generic Yasmin 28 3-0.03mg sold as:
Drospir/Ethi 3-0.03mg
Ocella 3-0.03mg
Syeda 3-0.03mg
Zarah 3-0.03mg
Zumandimine 3-0.03mg

Generic Yaz 3-0.02mg sold as:
Drospir/Ethi 3-0.02
Drospironone/ethy est
Glanvi
Jasmiei
Lo-Zumandimi
Loryna
Nikki
Vestura

Progestin Only Birth Control Pills

Generic Ortho Micronor & Noe-QD sold as:
Camila 0.35mg
Debitane
Errin 0.35mg
Heather 0.35mg
Incassia 0.35mg
Jencycla 0.35mg
Joliette 0.35mg
Lyza 0.35mg
Nora-Be 0.35mg
Norethindron 0.35mg
Norlyda 0.35mg
Norlyroc
Sharobel
Tulana 0.35mg
Slynd

Birth Control Rings (Vaginal)

Annovera
Nuva-Ring

Birth Control Patches (Transdermal)

Generic Ortho Evra sold as:
Xulane

Birth Control Shots (Injection)

Medroxyprogesterone 150mg IM (Generic Depo-Provera contraceptive)

Emergency Birth Control

ella
Levonorgestrel 1.5mg, (generic Plan B One-Step)

Over-The-Counter (OTC) Birth Control (must have a prescription and get them from a network pharmacy for OptumRx to cover the costs)

Contraceptive films (e.g. VCF Vaginal)
Contraceptive foams (e.g. VCF Vaginal Aert)
Contraceptive gels (e.g. Gynol II, Shur-Seal, VCF Vaginal)
FC female (female condom)
Generic emergency birth control (e.g. Aftera, EContra EZ, EContra OS, Levonorgestrel tab 1.5mg, My Choice, My Way, New Day, Next Choice, Opckon, Option 2, React, Take Action)

Today Sponge

Birth Control IUD's and Implants

Kyleena
Liletta
Mirena
Nexplanon
Paragard
Skyla

Some methods of birth control, such as IUDs and implants, may be available through your medical benefit and not your pharmacy benefit.

References:

- <https://one.walmart.com/content/dam/themepage/pdfs/OptumRxPreventiveCareMedications-2020.pdf>
- [https://mynmhc.org/\\$0-medications-list.pdf](https://mynmhc.org/$0-medications-list.pdf)

CVS Preventative Care List Adoption

\$0 Cost Share Products

LET'S TALK PREVENTION



October 2019

YOUR NO-COST PREVENTIVE SERVICES

Preventive services help you stay healthy. A doctor isn't someone to see only when you're sick. Doctors also provide services that help prevent medical problems and help keep you healthy. Staying healthy can help you:

- Live a fuller life
- Save your hard-earned money

Your health plan now offers certain preventive service benefits at no cost to you. This means you don't have to pay a copay* or coinsurance, even if you haven't met your deductible. These no-cost benefits are part of the Affordable Care Act (ACA). They include:

- Medicine and supplements to prevent certain health conditions for adults, women and children
- Medicine and products for quitting smoking or chewing tobacco (tobacco cessation)
- Medicine used prior to screenings for certain health conditions in adults
- Vaccines and immunizations to prevent certain illnesses in infants, children and adults
- Contraceptives for women

CVS Caremark® works with your health plan to provide these benefits. The following lists¹ explain:

- Which medicines, supplements, health-related products or vaccines are covered
- Who they are covered for (such as children up to age six or adults age 65 or older)
- What health condition or illness they help prevent
- Other important information

TIPS FOR USING THE LISTS

- Take these lists with you each time you or your family has a checkup or yearly exam.

- **Your doctor must write a prescription for these preventive services to be covered by your plan, even if they are listed as over-the-counter.**
- The dosage form is how the product is supplied. For example, tablet, capsule, liquid, syrup or chewable tablet.
- "Generic" or "brand name" is listed if only that product type is covered.
- Treatment recommendations may vary. Please call your doctor or pharmacist if you have questions about your health or medicine¹.
- Other rules, limits and exclusions may apply. Please contact your health plan to learn about your coverage¹.
- An exceptions process is available for circumstances that fall outside the listed preventive services – such as, for example, a request for coverage of a brand name product because the listed generic products are not medically appropriate. A process is also available for coverage of preventive services without cost sharing for plan members identifying with a gender that differs from the member's sex assigned at birth – such as, for example, a request for coverage of contraceptives or primary prevention of breast cancer for transgender members.

LEGEND:

chew = chewable	oral = taken by mouth
cap = capsule	OTC = over-the-counter product
FE = ferrous sulfate (iron)	Rx = prescription product
EE = ethinyl estradiol	soln = solution
hr = hour	SR = sustained release
IM = intramuscular	susp = suspension
IU = international unit	tab = tablet
mg = milligram	TD = transdermal
mL = milliliter	

WOMEN'S HEALTH PREVENTIVE SERVICES¹

OTHER CONTRACEPTIVES¹

- Generics and brand name only if a generic isn't available
- Generics are in *italics>. Brand-names are CAPITALIZED*
- Brand name will no longer be supplied at no cost when the generic becomes available
- Brand names listed in *[blue]* and in brackets are for your reference only

Brand-Name Oral Contraceptives (Rx)

- BALCOLTRA
- LO LOESTRIN FE
- NATAZIA
- SLYND
- TAYTULLA

Intrauterine Devices, Subdermal Rods and Vaginal Rings (Rx)

- NEXPLANON
- MIRENA
- SKYLA
- LILETTA
- KYLEENA
- PARAGARD T 380A
- NUVARING
- ANNOVERA

Transdermal Patches (Rx)

- Xulane

Injectables (Rx)

- DEPO-SUBQ-PROVERA 104
- Medroxyprogesterone acetate 150 mg
- [DEPO-PROVERA]

Barrier Methods (Rx)

Diaphragms

- MILEX WIDE-SEAL
- OMNIFLEX COIL SPRING SILICONE
- CAYA

Cervical Caps

- FEMCAP

Emergency Contraception (Rx or OTC)

- ELLA
- Levonorgestrel 1.5 mg tablet, *Aftera, Eontra EZ, Eontra OS, My Choice, My Way, New Day, Opicon, Option 2, Preventeza, Take Action, React [PLAN B]*

Female Condoms (OTC)

- FC-2

Vaginal Sponge (OTC)

- TODAY

Spermicides (OTC)

- ENCARE VAGINAL SUPPOSITORIES
- GYNOL II GEL 3%
- Monoxynol-9 vaginal gel 4%, VCF Vaginal Contraceptive Gel [CONCEPTROL GEL 4%]
- SHUR-SEAL GEL 2%
- VCF VAGINAL FILM 28%
- VCF VAGINAL FOAM 12.5%

BREAST CANCER PREVENTION

Primary Prevention of Breast Cancer in women¹ 35 years of age and older, who are at an increased risk.

Generic, oral tablets (Rx)

- Raloxifene HCl tab 60 mg
- Tamoxifen citrate tab 10 mg and 20 mg

References:

1. https://www.caremark.com/portal/asset/NoCost_Preventive_List.pdf

ANNOVERA Deal Terms

Milestone Payments

- Upon FDA approval: \$20M**
- First commercial batch release: \$20M**
- \$200M in cumulative net sales: \$40M
- \$400M in cumulative net sales: \$40M
- \$1B in cumulative net sales: \$40M

Royalty %

- Step structure:
- Annual net sales \leq \$50M: 5%
- Annual net sales $>$ \$50M and \leq \$150M: 10%
- Annual net sales $>$ \$150M: 15%

Additional Cost Considerations

- TXMD and Population Council jointly responsible for one observational PMR study*

*Costs exceeding \$20M to be shared with Population Council

**Already paid by TXMD to Population Council